These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2035893)

  • 21. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.
    Marasini B; Biondi ML; Bianchi E; Dell'Orto P; Agostoni A
    Eur J Clin Pharmacol; 1988; 35(4):419-21. PubMed ID: 3197751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism of action of ketanserin in hypertension and vasospastic disease.
    Wenting GJ; Brouwer RM; vd Meiracker AJ; Man in't Veld AJ; Schalekamp MA
    Acta Cardiol; 1987; 42(5):339-54. PubMed ID: 2827406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon.
    Hayoz D; Bizzini G; Noël B; Depairon M; Burnier M; Fauveau C; Rouillon A; Brouard R; Brunner HR
    Rheumatology (Oxford); 2000 Oct; 39(10):1132-8. PubMed ID: 11035135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Computerized digital thermometry in Raynaud's disease. Personal experience].
    Ponte E; Cafagna D; Cattinelli S
    Minerva Med; 1998; 89(7-8):259-66. PubMed ID: 9824987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin.
    Pola P; Tondi P; Serricchio M; Favuzzi A; Gerardino L
    Angiology; 1993 Feb; 44(2):123-8. PubMed ID: 8434805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microcirculatory and clinical effects of serial percutaneous application of carbon dioxide in primary and secondary Raynaud's phenomenon.
    Schmidt J; Monnet P; Normand B; Fabry R
    Vasa; 2005 May; 34(2):93-100. PubMed ID: 15968890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
    Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P
    Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects.
    Kallenberg CG; Wouda AA; Kuitert JJ; Tijssen J; Wesseling H
    J Rheumatol; 1987 Apr; 14(2):284-90. PubMed ID: 3598997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
    Finch MB; Dawson J; Johnston GD
    Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cold hands after exposure to arsenic or vibrating tools: effects of ketanserin on finger blood pressure and skin temperature.
    Lagerkvist BE; Linderholm H
    Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):327-32. PubMed ID: 2943135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regional intravenous ketanserin and guanethidine therapy in Raynaud's phenomenon.
    Caputi CA; De Carolis G; Tomasetti C
    Angiology; 1991 Jun; 42(6):473-80. PubMed ID: 2042796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ketanserin versus nifedipine in secondary Raynaud's phenomenon.
    Kirch W; Linder HR; Hutt HJ; Ohnhaus EE; Mahler F
    Vasa; 1987; 16(1):77-80. PubMed ID: 3554811
    [No Abstract]   [Full Text] [Related]  

  • 34. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reproducibility of cold provocation in patients with Raynaud's phenomenon.
    Wigley FM; Malamet R; Wise RA
    J Rheumatol; 1987 Aug; 14(4):751-5. PubMed ID: 3668980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.
    Seibold JR; Terregino CA
    J Rheumatol; 1986 Apr; 13(2):337-40. PubMed ID: 2941573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New treatments for Raynaud's syndrome].
    Bellucci S; Kedra W; Ajzenberg N; Tobelem G; Caen J
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):103-7. PubMed ID: 3290833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Digital pressure and flow measurement upon local cooling in Raynaud's disease. Effect of naftidrofuryl.
    Bounameaux HM; Hellemans H; Verhaege R
    Int Angiol; 1986; 5(1):39-44. PubMed ID: 3734514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon.
    Wise RA; Wigley F
    J Rheumatol; 1994 Jan; 21(1):80-3. PubMed ID: 8151594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The therapy of Raynaud's phenomenon].
    Di Giacinto G
    Clin Ter; 1993 Feb; 142(2):161-74. PubMed ID: 8472530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.